Issue link: https://www.e-digitaleditions.com/i/1497323
48 Pharmaceutical Technology ® The Real Message Behind Commercial mRNA Products April eBook 2023 PharmTech.com AnAly tics References 1. Webb, C.; Ip, S.; Bathula, N. V.; et al. Current Status and Future Perspectives on MRNA Drug Manufacturing. Mol. Pharm. 2022, 19 (4), 1047–1058. DOI: 10.1021/acs.molphar‑ maceut.2c00010 2. Santos, I.A.; Grosche, V. R.; Bergamini, F. R. G.; et al. Anti‑ virals Against Coronaviruses: Candidate Drugs for SARS‑ CoV‑2 Treatment? Front. Microbiol. 2020, 11, 1818. DOI: 10.3389/fmicb.2020.01818 3. Huang, L.; Zhang, L.; Li, W.; et al. Advances in Development of mRNA‑Based Therapeutics. Curr. Top Microbiol. Immunol. 2020, Epub ahead of print. DOI: 10.1007/82_2020_222 4. Van Hoecke, L.; Roose, K. How mRNA Therapeutics are En‑ tering the Monoclonal Antibody Field. J. Transl. Med. 2019, 17 (1), 54. DOI: 10.1186/s12967‑019‑1804‑8 5. Kim, Y. K. RNA Therapy: Rich History, Various Applications and Unlimited Future Prospects. Exp. Mol. Med. 2022, 54 (4), 455–465. DOI: 10.1038/s12276‑022‑00757‑5 6. Thakur, R. mRNA: Therapeutics and Global Markets. BCC Research: Online 2021. 7. Poveda, C.; Biter, A. B.; Bottazzi, M. E.; Strych, U. Establish‑ ing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. Vaccines 2019, 7 (4) 131. DOI: 10.3390/vaccines7040131 8. Sergeeva, O. V.; Koteliansky, V. E.; Zatsepin, T. S. mR‑ NA‑Based Therapeutics–Advances and Perspectives. Biochemistry (Mosc). 2016, 81 (7), 709–22. DOI: 10.1134/ S0006297916070075 9. Eu ropea n Med ici nes Agenc y, Guideline on the Qual- it y, Non Clinical And Clinical A spects of Gene T herapy Medicinal Products. 2018. 10. World Health Organization, Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations. 2021. 11. Knezevic, I.; Liu, M. A.; Peden, K.; Zhou, T.; Kang, H. ‑N. Development of m R NA Vacci nes: Scient i f ic a nd Regulatory Issues. Vaccines (Basel) 2021, 9 (2), 81. DOI: 10.3390/vaccines9020081 12. Pardi, N.; Hogan, M. J.; Porter, F. W.; Weissman, D. mRNA Vaccines — A New Era in Vaccinology. Nature Reviews Drug Discovery 2018, 17 (4), 261–279. DOI: 10.1038/nrd.2017.243 13. Ouranidis, A.; Vavilis, T.; Mandala, E.; et al. mRNA Ther‑ apeutic Modalities Design, Formulation and Manufactur‑ ing under Pharma 4.0 Principles. Biomedicines 2022, 10 (1), PMC8773365. DOI: 10.3390/biomedicines10010050 14. Lukavsky, P. J.; Puglisi, J. D. Large‑Scale Preparation and Purification of Polyacrylamide‑Free RNA Pligonucleotides. RNA 2004, 10 (5), 889–93. DOI: 10.1261/rna.5264804 15. Kim, I.; Mckenna, S. A.; Puglisi, E. V.; Puglisi, J. D. Rapid Purifi‑ cation of RNAs Using Fast Performance Liquid Chromatogra‑ phy (FPLC). RNA 2007, 13 (2), 289–94. DOI: 10.1261/rna.342607 16. Kariko, K.; Muramatsu, H.; Ludwig, J.; Weisman, D. Gener‑ ating the Optimal mRNA for Therapy: HPLC Purification Eliminates Immune Activation and Improves Translation of Nucleoside‑Modified, Protein‑Encoding mRNA. Nucleic Acids Res. 2011, 39 (21), e142. DOI: 10.1093/nar/gkr695 17. BIA Separations, Application note AN062: Purification of Messenger RNA by Affinity Chromatography on CIMmul‑ tus Oligo dT Column. 2019. 18. Beverly, M.; Dell, A.; Parmar, P.; Houghton, L. Label‑Free Analysis of mRNA Capping Efficiency Using RNase H Probes and LC‑MS. Anal. Bioanal. Chem. 2016, 408 (18), 5021–30. DOI: 10.1007/s00216‑016‑9605‑x 19. Stepinski, J.; Waddell, C.; Stolarski, R.; Darzynkiewicz, E.; Rhoads, R. E. Synthesis and Properties of mRNAs Con‑ taining the Novel "Anti‑Reverse" Cap Analogs 7‑meth‑ yl(3'‑O‑methyl)GpppG and 7‑methyl(3'‑deox y)GpppG. RNA 2001, 7, 1486–1495. 20. Bei l harz, T. H.; Preiss, T. Widespread Use of Poly(A) Tail Leng th Control to Accentuate Expression of the Yeast Tra nscr iptome. R NA 2007, 13 (7), 982–97. DOI: 10.1261/rna.569407 21. Beverly, M.; Hagen, C.; Slack, O. Poly A Tai l Leng t h Analysis of In Vitro Transcribed mRNA by LC‑MS. Anal. Bioanal. Chem. 2018, 410 (6), 1667–1677. DOI: 10.1007/s00216‑ 017‑0840‑6 22. Liau, B. Agilent application note, Analysis of mRNA Poly‑A Sequence Variants by High‑Resolution LC/MS. 2021. 23. Stark, R.; Grzelak, M.; Hadfield, J. RNA Sequencing: The Teenage Years. Nat. Rev. Genet. 2019, 20 (11), 631–656. DOI: 10.1038/s41576‑019‑0150‑2 24. Jiang, T.; Yu, N.; Kim, J.; et al. Oligonucleotide Sequence Mapping of Large Therapeutic mRNAs via Parallel Ribo‑ nuclease Digestions and LC‑MS/MS. Anal. Chem. 2019, 91 (13), 8500–8506. DOI: 10.1021/acs.analchem.9b01664 25. Va n h i n sberg h, C. J.; Cr i sc uolo, A.; Sut ton, J. N.; et al. Characterization and Sequence Mapping of Large RNA and mRNA Therapeutics Using Mass Spectrometry. Anal. Chem. 2022, 94 (20), 7339–7349. DOI: 10.1021/acs.anal‑ chem.2c00765 26. Sut ton, J. M.; Gui ma raes, G. J.; A n nava rapu, V.; va n Dongen, W. D.; Bar tlett, M. G. Current State of Oligo‑ nucleotide Characterization Using Liquid Chromatog‑ raphy‑Mass Spectrometr y: Insight into Critical Issues. J. Am. Soc. Mass Spectrom. 2020, 31 (9), 1775–1782. DOI: 10.1021/jasms.0c00179 27. Lobue, P. A.; Jora, J.; Addepalli, B.; Limbach, P. A. Oligo‑ nucleotide Analysis by Hydrophilic Interaction Liquid Chromatography‑Mass Spectrometr y in the Absence of Ion‑Pair Reagents. J. Chromatogr. A 2019, 1595, 39–48. DOI: 10.1016/j.chroma.2019.02.016 28. Yu, Y.; Zhu, S. ‑H.; Yuan, F.; et al. Ultrasensitive and Simul‑ taneous Determination of RNA Modified Nucleotides by Sheathless Interfaced Capillary Electrophoresis‑Tandem Mass Spectrometry. Chem. Commun. (Camb). 2019, 55 (53), 7595–7598. DOI: 10.1039/C9CC03195B 29. Gilar, M.; Fountain, K. J.; Budman, Y.; et al. Ion‑Pair Re‑ versed‑Phase High‑Performance Liquid Chromatography Analysis of Oligonucleotides: Retention Prediction. Journal of Chromatography A 2002, 958 (1–2), 167–82. DOI: 10.1016/ s0021‑9673(02)00306‑0 30. Kanavarioti, A. HPLC Methods for Purity Rvaluation of